Cancer Research Cell Death Mechanisms and Cancer Therapy  Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wilson, W. R.
Right arrow Articles by Denny, W. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wilson, W. R.
Right arrow Articles by Denny, W. A.
[Cancer Research 62, 1425-1432, March 1, 2002]
© 2002 American Association for Cancer Research


Experimental Therapeutics

Quantitation of Bystander Effects in Nitroreductase Suicide Gene Therapy Using Three-Dimensional Cell Cultures1

William R. Wilson2, Susan M. Pullen, Alison Hogg, Nuala A. Helsby, Kevin O. Hicks and William A. Denny

Auckland Cancer Society Research Centre, The University of Auckland, Private Bag 92019, Auckland, New Zealand

The efficacy of cancer gene therapy depends critically on "bystander effects" by which genetic modification of tumor cells results in killing of unmodified cells in the local microenvironment. In gene-dependent enzyme-prodrug therapy, expression of a prodrug-activating suicide gene is used to generate a cytotoxic metabolite that diffuses to nontransduced cells. The objective of this study was to develop a physiologically relevant tissue culture model for quantifying bystander effects and to validate the model using as an example the activation of dinitrobenzamide prodrugs (e.g., CB 1954) by Escherichia coli aerobic nitroreductase (NTR). Bystander effects were measured in three-dimensional multilayer cocultures of NTR+ and NTR- cells by determining clonogenic survival curves for both cell types using V79, Skov3, or WiDr as parental cell lines. Bystander killing by CB 1954 was much more efficient in multilayers than monolayers at equivalent cell:medium ratios, whereas the chloromustard analogue of CB 1954 showed even greater efficiency. For a series of dinitrobenzamides, bystander killing in multilayers showed a positive correlation with prodrug lipophilicity and also correlated with the bystander effect in mixed tumor xenografts grown from the same NTR+ and NTR- WiDr cell lines (r2 = 0.84; P < 0.001). The multilayer model identified a bromomustard prodrug (SN 24927) with superior therapeutic activity to CB 1954 that provided curative activity against WiDr tumors comprising 1:1 mixtures of NTR+ and NTR- cells. This study demonstrates the utility of the multilayer tissue culture model for quantifying and optimizing bystander effects in tumors and identifies a new lead prodrug for NTR gene-dependent enzyme-prodrug therapy.




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
N. A. Helsby, M. A. Goldthorpe, M. H. Y. Tang, G. J. Atwell, E. M. Smith, W. R. Wilson, and M. D. Tingle
Influence of Mustard Group Structure on Pathways of in Vitro Metabolism of Anticancer N-(2-Hydroxyethyl)-3,5-dinitrobenzamide 2-Mustard Prodrugs
Drug Metab. Dispos., February 1, 2008; 36(2): 353 - 360.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. V. Patterson, D. M. Ferry, S. J. Edmunds, Y. Gu, R. S. Singleton, K. Patel, S. M. Pullen, K. O. Hicks, S. P. Syddall, G. J. Atwell, et al.
Mechanism of Action and Preclinical Antitumor Activity of the Novel Hypoxia-Activated DNA Cross-Linking Agent PR-104
Clin. Cancer Res., July 1, 2007; 13(13): 3922 - 3932.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
C.-Q. Ling, B. Li, C. Zhang, D.-Z. Zhu, X.-Q. Huang, W. Gu, and S.-X. Li
Inhibitory effect of recombinant adenovirus carrying melittin gene on hepatocellular carcinoma
Ann. Onc., January 1, 2005; 16(1): 109 - 115.
[Abstract] [Full Text] [PDF]


Home page
J Biomol ScreenHome page
L. A. Kunz-Schughart, J. P. Freyer, F. Hofstaedter, and R. Ebner
The Use of 3-D Cultures for High-Throughput Screening: The Multicellular Spheroid Model
J Biomol Screen, June 1, 2004; 9(4): 273 - 285.
[Abstract] [PDF]


Home page
Cancer Res.Home page
J. I. Grove, A. L. Lovering, C. Guise, P. R. Race, C. J. Wrighton, S. A. White, E. I. Hyde, and P. F. Searle
Generation of Escherichia Coli Nitroreductase Mutants Conferring Improved Cell Sensitization to the Prodrug CB1954
Cancer Res., September 1, 2003; 63(17): 5532 - 5537.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.